No profile data available.
Altimmune, Inc. (ALT) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Gaithersburg, United States, with about 57 full-time employees.
It reported revenue of $41,000 for fiscal year 2025, up 105.0% from fiscal year 2024, and net income of -$88.09 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $507.69 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Altimmune reported $41,000 in revenue for fiscal year 2025, up 105.0% from $20,000 in fiscal year 2024. In Q2 2026 revenue was $0.
$507.69 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Emergent BioSolutions Inc. (EBS), Silence Therapeutics plc (SLN), Oculis Holding AG (OCS), Contineum Therapeutics, Inc. (CTNM).